Hikma Pharmaceuticals Plc FTC preliminary approval for Custopharm (6696I)

TIDMHIK

RNS Number : 6696I

Hikma Pharmaceuticals Plc

20 April 2022

London, 20 April 2022 - Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today confirms it has received preliminary approval from the US Federal Trade Commission (FTC) and will now work towards closing its acquisition of Custopharm Inc. from Water Street Healthcare Partners, as previously announced on 27 September 2021. The parties have now obtained all regulatory approvals required to close the transaction. Hikma will make a further announcement upon the close of the transaction.

- ENDS -

Enquiries:

Hikma (Investors):

 
Susan Ringdal 
 EVP, Strategic Planning and Global   +44 (0)20 7399 2760/ +44 (0)7776 
 Affairs                               477050 
Guy Featherstone                      +44 (0)20 3892 4389/ +44 (0)7795 
 Senior Investor Relations Manager     896738 
Layan Kalisse                         +44 (0)20 7399 2788/ +44 (0)7970 
 Investor Relations Analyst            709912

Teneo (Press):

 
                                        +44 (0)7703 330 269/ +44 (0)7464 
                                         982426 
Charles Armitstead/Camilla Cunningham 
 
 US Media 
 Steven Weiss/David Belian               +1 732 788 8279/ +1 848 254 4875

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEAELNFDAAEAA

(END) Dow Jones Newswires

April 20, 2022 02:10 ET (06:10 GMT)

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024